IFNB1 and myeloid sarcoma: In addition, by acting on peripheral T-cells, interferon-beta (IFN-β) is thought to reduce disease activity, with an MRI-detectable effect in relapsing–remitting multiple sclerosis (RR-MS) patients [4-6], confirming the critical role of peripheral blood mononuclear cells (PBMCs) in CNS damage [7].